9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Integrating interventional oncology in the treatment of liver tumors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          Percutaneous ablation techniques offer a vast armamentarium for local, minimally invasive treatment of liver tumors, nowadays representing an established therapeutic option, which is integrated in treatment algorithms, especially for non-resectable liver tumors. The results of ablative treatment compare very well to surgical treatment in liver lesions, and confirm that these techniques are a valuable option for bridging for transplantation. Different techniques have been established to perform tumor ablation, and the feasibility varies according to the procedure and technical skills of the operator, depending on the size and location of the liver lesion. In recent years, stereotactic multi-needle techniques using 3D trajectory planning, general anesthesia, and tube disconnection during needle placement have had a strong impact on the application range of ablation for liver tumors.

          Conclusion

          It is well known that creating a sufficient ablation margin and overlapping ablation zones is one key issue to enable ablation of large liver lesions with tumor-free margins (A0 ablation in analogy to R0 resection). Image fusion during treatment and follow-up assure highly accurate staging procedures and interventional planning.

          Novel aspects

          Review on the standards in ablation techniques for the treatment of liver tumors. Update on different ablation techniques, indications, and contraindications for percutaneous liver tumor treatment. Summary of recently published reports on liver tumor ablation.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

          There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

            If liver transplantation is not feasible, partial resection is considered the treatment of choice for hepatocellular carcinoma (HCC) in patients with cirrhosis. However, in some centers the first-line treatment for small, single, operable HCC is now radiofrequency ablation (RFA). In the current study, 218 patients with single HCC
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

              To report complications encountered by members of a collaborative group who performed radio-frequency (RF) ablation in patients with focal liver cancer. Members of 41 Italian centers that were part of a collaborative group used a percutaneous internally cooled RF ablation technique and a standardized protocol for follow-up. They completed a questionnaire regarding number of deaths, presumed cause of death, and likelihood of its relationship to the RF procedure; number and types of major complications; and types of minor complications and side effects. Enrollment included 2,320 patients with 3,554 lesions (size, 3.1 cm +/- 1.1 [SD] in diameter): 1,610 had hepatocellular carcinoma with chronic liver disease; 693 had metastases, predominantly from colorectal cancer (n = 501); and 17 had cholangiocellular carcinoma. Number and characteristics of complications (ie, deaths and major and minor complications) attributed to the procedure were reported. Data were subsequently analyzed with analysis of variance to determine whether the major complication rate was related to tumor size, number of ablation sessions, or electrode type (single or cluster). In total, 3,554 lesions were treated. Six deaths (0.3%) were noted, including two caused by multiorgan failure following intestinal perforation; one case each of septic shock following Staphylococcus aureus-caused peritonitis, massive hemorrhage following tumor rupture, liver failure following stenosis of right bile duct; and one case of sudden death of unknown cause 3 days after the procedure. Fifty (2.2%) patients had additional major complications. The most frequent of these were peritoneal hemorrhage, neoplastic seeding, intrahepatic abscesses, and intestinal perforation. An increased number of RF sessions were related to a higher rate of major complications (P <.01), whereas the number of complications was not significantly different when tumor size or electrode type were compared. Minor complications were observed in less than 5% of patients. Results of this study confirm that RF ablation is a relatively low-risk procedure for the treatment of focal liver tumors.
                Bookmark

                Author and article information

                Contributors
                +43-512-50480540 , reto.bale@i-med.ac.at
                Journal
                Eur Surg
                Eur Surg
                European Surgery
                Springer Vienna (Vienna )
                1682-8631
                1682-4016
                13 April 2018
                13 April 2018
                2018
                : 50
                : 3
                : 117-124
                Affiliations
                [1 ]ISNI 0000 0000 8853 2677, GRID grid.5361.1, Department of Radiology, , Medical University Innsbruck, ; Anichstr. 35, 6020 Innsbruck, Austria
                [2 ]ISNI 0000 0000 8853 2677, GRID grid.5361.1, Department of Surgery, , Medical University Innsbruck, ; Innsbruck, Austria
                Author information
                http://orcid.org/0000-0002-1864-8900
                Article
                521
                10.1007/s10353-018-0521-5
                5968075
                9d372a5c-7697-4c17-a6dc-dc3ed980a5dd
                © The Author(s) 2018

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 25 January 2018
                : 23 March 2018
                Categories
                Main Topic
                Custom metadata
                © Springer-Verlag GmbH Austria, part of Springer Nature 2018

                radiofrequency ablation,liver tumor treatment,percutaneous tumor treatment,interventional oncology,minimally invasive oncology

                Comments

                Comment on this article